DR. SHARAD MALAVADE MD
Prescription History 1871970608
Internal Medicine in Brandon, FL

NPI Status: Active since April 30, 2015

Contact Information

119 OAKFIELD DRIVE
BRANDON, FL
ZIP 33511
Phone: (813) 571-6451

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SHARAD MALAVADE MD, an active Internal Medicine specialist practicing in Brandon, FL. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 151 documented patient claims. Among these therapy options, the most frequently utilized medication is Daptomycin, which accounts for 52 claims alone.

Medication Index


Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
FL State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills100.6
Peer Average Days Supply3,011
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.8% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,561.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,130.16

State Avg Cost Per Claim

$3,874.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefepime Hcl

Generic Formulation: Cefepime HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 114
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply179
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,984.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$299.23

State Avg Cost Per Claim

$245.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Therapeutic Applications

Cefepime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 91
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply156
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $678.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.18

State Avg Cost Per Claim

$82.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 339
FL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply195
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 73.3% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,097.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$328.80

State Avg Cost Per Claim

$1,343.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Nuzyra

Generic Formulation: Omadacycline TosylateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
FL State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.4
Peer Average Days Supply254
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,938.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,911.51

State Avg Cost Per Claim

$7,488.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Omadacycline is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Piperacillin-Tazobactam

Generic Formulation: Piperacillin Sodium/TazobactamSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 124
FL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply123
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,010.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$316.34

State Avg Cost Per Claim

$239.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.

Therapeutic Applications

Piperacillin/tazobactam is used to treat a wide variety of bacterial infections. It is a penicillin antibiotic. It works by stopping the growth of bacteria.

Voriconazole

Generic Formulation: VoriconazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
FL State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply468
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,203.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$350.25

State Avg Cost Per Claim

$462.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.

Therapeutic Applications

Voriconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Xerava

Generic Formulation: Eravacycline Di-HydrochlorideSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 64
FL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply183
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,642.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$876.61

State Avg Cost Per Claim

$1,299.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eravacycline is used to treat certain abdominal infections (such as appendicitis, diverticulitis, gastric/intestinal perforation). This medication belongs to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SHARAD MALAVADE MD provides transparency into local medical care patterns within Brandon, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.